Skip to content

A prospective, multicenter, single group clinical trial to evaluate the efficacy and safety of nanosecond pulse tumor ablation system and disposable electric pulse ablation electrode in the treatment of prostate cancer

A prospective, multicenter, single group clinical trial to evaluate the efficacy and safety of nanosecond pulse tumor ablation system and disposable electric pulse ablation electrode in the treatment of prostate cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200066216
Enrollment
Unknown
Registered
2022-11-28
Start date
2022-12-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Single group:Pulsed electric field ablation

Sponsors

RenJi Hospital Affiliated to Shanghai Jiaotong University School of Medical
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
40 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Male above the age of 40 (including 40 years old); 2) Preoperative pathological analysis or imaging diagnosis of untreated prostate cancer, satisfying the tumor T stage of T1a-T2c, Gleason score =5 years; 6) The subject or his/her legal guardian can understand the study purpose, demonstrate adequate compliance with the study protocol, and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients who have received any previous treatment for prostate cancer, including but not limited to surgery, hormone therapy, chemotherapy, radiotherapy, targeted therapy and immunotherapy; 2) Complicated with other malignant tumors, or in the acute infection phase or other severe infections, such as severe urinary system infection; 3) Electronic devices and metal parts such as pacemakers or defibrillators are implanted in or near the ablation area; 4) Patients with a history of severe arrhythmia, epilepsy or recent large-scale myocardial infarction; 5) Complicated with serious heart, liver, kidney, brain disease or coagulopathy; 6) Patients who have participated in clinical studies of other drugs, biologics or devices within 3 months; 7) Situations in which other investigators deem it inappropriate to participate in clinical trials.

Design outcomes

Primary

MeasureTime frame
Detection rate of clinically significant prostate cancer;

Secondary

MeasureTime frame
Evaluation of solid tumor ablation (mRECIST);Biochemical recurrence rate of serum PSA;International Prostate Symptom Score;Normal urinary control rate;International erectile function score 5 items;Evaluation on the convenience of device use;Device stability evaluation;

Countries

China

Contacts

Public ContactWei Xue

RenJi Hospital Affiliated to Shanghai Jiaotong University School of Medical

uroxuewei@163.com13801931604

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026